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Abstract
Pathogenic de novo variants in the X‐linked gene SLC35A2 encoding the major
Golgi‐localized UDP‐galactose transporter required for proper protein and lipid glycosyla-
tion cause a rare type of congenital disorder of glycosylation known as SLC35A2‐
congenital disorders of glycosylation (CDG; formerly CDG‐IIm). To date, 29 unique de novo
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variants from 32 unrelated individuals have been described in the literature. The majority
of affected individuals are primarily characterized by varying degrees of neurological
impairments with or without skeletal abnormalities. Surprisingly, most affected individuals
do not show abnormalities in serum transferrin N‐glycosylation, a common biomarker for
most types of CDG. Here we present data characterizing 30 individuals and add 26 new
variants, the single largest study involving SLC35A2‐CDG. The great majority of these
individuals had normal transferrin glycosylation. In addition, expanding the molecular and
clinical spectrum of this rare disorder, we developed a robust and reliable biochemical
assay to assess SLC35A2‐dependent UDP‐galactose transport activity in primary
fibroblasts. Finally, we show that transport activity is directly correlated to the ratio of
wild‐type to mutant alleles in fibroblasts from affected individuals.
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1 | INTRODUCTION
Congenital disorders of glycosylation (CDG) are an expanding group of
metabolic diseases that primarily present with neurological involvement
but can affect all organ systems depending on the specific CDG type
(Freeze, Eklund, Ng, & Patterson, 2012; Freeze, Eklund, Ng, & Patterson,
2015). The majority of these defects can be initially identified by
carbohydrate‐deficient transferrin (CDT) analysis, which examines the
glycosylation status of the abundant serum protein, transferrin (Tf;
Freeze, 2006; Lacey, Bergen, Magera, Naylor, & O'Brien, 2001). While
this is a reliable screening tool for identifying individuals with CDG, it
cannot indicate the gene responsible for that disorder. Thus far, the vast
majority of CDG types are rare autosomal recessive or X‐linked disorders
(Ferreira et al., 2018), but as more affected individuals have undergone
next‐generation sequencing (NGS), reports of pathogenic de novo
variants are becoming more common (Ng & Freeze, 2018).
SLC35A2 (MIM# 314375) is an X‐linked gene, encoding the
primary UDP‐galactose transporter in humans (Hara et al., 1993;
Ishida, Miura, Yoshioka, & Kawakita, 1996; Miura et al., 1996). It
belongs to the SLC35A family of nucleotide sugar transporters, which
also includes the characterized transporters, SLC35A1 (CMP‐sialic
acid), and SLC35A3 (UDP‐N‐acetylglucosamine; Deutscher, Nuway-
hid, Stanley, Briles, & Hirschberg, 1984; Guillen, Abeijon, &
Hirschberg, 1998), as well as two putative nucleotidesugar carriers
SLC35A4 and SLC35A5 with unknown substrate specificity.
Using mammalian cell‐based models, it has been demonstrated that
inactivation of SLC35A2 protein abolishes transport of UDP‐galactose
into the Golgi apparatus, resulting in the synthesis of truncated glycans
lacking galactose (Brandli, Hansson, Rodriguez‐Boulan, & Simons,
1988; Ishida et al., 1999; Oelmann, Stanley, & Gerardy‐Schahn,
2001). These include N‐ and O‐linked glycans, glycosaminoglycan
(GAG), and glycosphingolipids (Brockhausen & Stanley, 2015; Lindahl,
Couchman, Kimata, & Esko, 2015; Schnaar & Kinoshita, 2015; Stanley,
Taniguchi, & Aebi, 2015). In 2013, whole exome sequencing (WES)
identified de novo SLC35A2 variants in the first three individuals with
SLC35A2‐CDG (MIM# 300896; Ng et al., 2013). The biochemical
analysis of primary fibroblasts from affected individuals supported the
pathogenicity of these variants (Ng et al., 2013).
To date, molecular and clinical information on 32 individuals with
de novo variants in SLC35A2 have been reported with most
exhibiting neurological symptoms, especially epilepsy, developmental
delay, and intellectual disability (Bosch et al., 2016; Bruneel et al.,
2018; Dorre et al., 2015; Euro, Epilepsy Phenome/Genome, & Epi,
2014; Kimizu et al., 2017; Kodera et al., 2013; Lelieveld et al., 2016;
Ng et al., 2013; Sim et al., 2018; Westenfield et al., 2018; Winawer
et al., 2018; Yates et al., 2018). Recently, WES analysis of brain
specimens from 56 individuals identified five subjects harboring
somatic de novo SLC35A2 variants (Winawer et al., 2018).
SLC35A2 is X‐linked and most affected individuals are females.
This is an important factor that could account for the variations seen
in both the biochemical and clinical phenotypes due to X‐chromo-
some inactivation (XCI). Females are inherently mosaic for X‐linked
genes because XCI will randomly silence one of their two allele. This
random inactivation can ultimately determine the degree to which an
allele is expressed (Galupa & Heard, 2018).
In this study, we characterized the molecular, clinical, and biochemical
data from a cohort of 30 individuals with SLC35A2‐CDG and developed
a biochemical assay to reliably measure SLC35A2‐dependent UDP‐
galactose transport into the Golgi apparatus of primary fibroblasts.
2 | MATERIALS AND METHODS
2.1 | Subjects and clinical information
Families included in our SLC35A2‐CDG research study provided
written consent under an approved Sanford Burnham Prebys Medical
Discovery Institute IRB protocol or an approved IRB through each
medical institution. The only inclusion criteria for this study were
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either the identification of de novo variants within SLC35A2 or the
identification of an abnormal CDT test result suggestive of a
galactosylation defect. Primary fibroblasts were grown from a skin
biopsy that was obtained by the subjects’ physician.
2.2 | Molecular analysis of SLC35A2
Variant analysis for SLC35A2 (NM_001042498.2, ENST00000376521.6)
was carried out using either direct Sanger sequencing of the five
coding exons or in many instances NGS (i.e., WES, whole genome
sequencing, targeted gene panels). Polymerase chain reaction
(PCR) primers and conditions are available upon request. NGS was
performed at multiple institutions, both commercial and academic
on different platforms; however, all variants were confirmed by
Sanger for all probands and available parents. All variants have
been submitted to the LOVD database (https://databases.lovd.nl/
shared/genes/SLC35A2).
2.3 | In vitro UDP‐galactose transport assay
Chinese hamster ovary (CHO), CHO‐Lec8 (Stanley, 1981), and
primary fibroblasts (Ichikawa, Scott, Losfeld, & Freeze, 2014) were
cultured as described. CHO‐Lec8 bearing a c.275_374del was used in
all experiments and are available from American Type Culture
Collection (CRL‐1737, Manassas, VA; Oelmann et al., 2001; Stanley,
1981). Cells were harvested at 70 to 80% confluence and
permeabilized using hypotonic conditions as described (Kim, Miura,
Etchison, & Freeze, 2001). Initially the glycoside concentration,
temperature and time of the assay were optimized using CHO and
CHO‐Lec8 cells. Thereafter, UDP‐galactose transport was always
carried out for 30min at 37°C using 27 nM UDP‐[6‐3H] galactose
(60 Ci/mmol; American Radiolabeled Chemicals Inc., Saint Louis, MO)
as a donor substrate and 1mM 4‐methylumbelliferyl β‐N‐acetylglu-
cosamine (GlcNAcβ−4‐MU; Sigma Aldrich) as an artificial acceptor in
dimethyl sulfoxide (DMSO; Sigma‐Aldrich), final concentration of 1%.
Before adding UDP‐[6‐3H] galactose to the reaction, permeabilized
cells were preincubated for 5min with GlcNAcβ−4‐MU at 37°C to
allow penetration of the glycoside. As a negative control, equal
volume of DMSO (final concentration 1%) was added instead of the
glycoside. After 30min the reaction product, [6‐3H] Galβ1,4GlcNAcβ
−4‐MU was extracted from the cells with 70% ethanol, purified on
Sep‐Pak 0.2 ml C18 columns (Waters Corporation, Milford, MA) and
the radioactive product measured as previously described (Kim et al.,
2001). For data statistical analysis, one‐way analysis of variance test
with Tukey’s post hoc test was used. All analyses were performed
with GraphPad Prism (GraphPad software, La Jolla, CA). Statistical
significance was assigned to p < 0.05.
Determination of kinetic parameters were performed in CHO
cells under optimized conditions, using increasing concentrations of
unlabeled UDP‐galactose (Sigma‐Aldrich) with 0.25 μCi 3H substrate.
Michaelis constant and Vmax for UDP‐galactose transport were
calculated as disintegrations per minute and determined using
nonlinear regression fit in GraphPad Prism.
2.4 | SLC35A2 complementary DNA allele ratios
A total of 500 ng RNA was isolated from primary fibroblasts
using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA) and
used for complementary DNA (cDNA) synthesis with QuantiTect
Reverse Transcription Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instruction. To determine the ratio of wild‐type
(WT) and mutant SLC35A2 alleles, specific primers were designed
to PCR amplify the region where each individual’s mutated
transcript was located. Importantly, each variant results in either
a gain or loss of the indicated restriction site (Figure S1) within
the PCR product. Restriction digestion was performed for 1 hr at
the temperature that is optimal for each enzyme, according to the
manufacturer’s instructions (New England Biolabs, Ipswich, MA).
As a control, PCR product amplified on cDNA derived from the
subject's cells was treated the same way, but restriction enzyme
was replaced with an equal volume of water. Both digested
and undigested PCR products were separated on 4% agarose gel
and visualized with ethidium bromide. ChemiDoc Imaging System
(Bio‐Rad Laboratories Inc., Hercules, CA) was used to document
the gels. Wild type to mutant allele ratios was estimated by
quantification of the intensity of mutant undigested PCR products
and comparing these to the intensity of the digested product
(Figure S2). For that purpose, the ImageJ software was used
(National Institutes of Health, Bethesda, MD). Restriction diges-
tion of each individual’s sample was performed in duplicate. PCR
conditions and primers are available upon request.
2.5 | Western blot analysis
Primary fibroblasts were lysed in 2% sodium dodecyl sulfate (SDS)
lysis buffer, subjected to SDS‐polyacrylamide gel electrophoresis and
transferred onto the polyvinylidene fluoride membrane. SLC35A2
protein was detected using rabbit anti‐SLC35A2 primary (Novus
Biologicals, Littleton, CO) and goat anti‐rabbit secondary antibodies
(SeraCare Life Sciences Inc., Milford, MA). α‐Tubulin was detected
with mouse primary (Developmental Studies Hybridoma Bank,
Iowa City, IA) and sheep anti‐mouse secondary antibodies (GE
Healthcare, Chicago, IL). Western blots analysis were performed as
previously described (Sosicka et al., 2017).
2.6 | Immunofluorescence staining
Endogenous UDP‐galactose transporter was detected using anti‐
SLC35A2 primary (Novus Biologicals, Littleton, CO) and goat anti‐
rabbit Alexa Fluor 568 secondary (Life Technologies, Carlsbad, CA)
antibodies diluted 1:400 and 1:200, respectively. Overexpressed
SLC35A2 protein was counterstained with mouse anti‐HA tag
(Thermo Fisher Scientific) primary and goat anti‐mouse Alexa‐Fluor
568 secondary (Life Technologies, Carlsbad, CA) antibodies diluted
1:500 and 1:200, respectively. Terminal N‐acetylgalactosamine
(GalNAc) in O‐glycans was detected either using Vicia villosa lectin
(VVL) conjugated with FITC (Vector Biolabs, Malvern, PA) diluted
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1:100 (fibroblasts) or biotinylated VVL lectin (Vector Biolabs) and
streptavidin conjugated with Cy3 (Sigma‐Aldrich) both diluted 1:100
(CHO cells). Nuclei were counterstained using DAPI (MP Biomedi-
cals, Santa Ana, CA). Immunofluorescence staining was performed as
previously described (Sosicka et al., 2017). CHO‐Lec8 cells were
imaged using Zeiss LSM510 confocal microscope and fibroblasts with
Zeiss LSM710 confocal microscope (Carl Zeiss, Oberkochen,
Germany).
2.7 | Generating CHO‐Lec8 stable clones
Introduction of each SLC35A2 variant was carried out using QuikChange
Site‐Directed Mutagenesis Kit according to the manufacturerʼs instruc-
tion (Agilent Technologies, Santa Clara, CA). PCR conditions as well as
primer sequences are available upon request. Parental CHO and the
Slc35a2 null CHO‐Lec8 cells were grown in F‐12K complete medium and
transfected with respective pSelect‐Zeo plasmid encoding either or
mutant SLC35A2 with an HA epitope at the N‐terminus, as previously
described (Sosicka, Jakimowicz, Olczak, & Olczak, 2014). Stable
transfectants were generated by culturing cells as mentioned above
supplemented with 200µg/ml Zeocin for 3 weeks.
3 | RESULTS
3.1 | Variant analysis
The majority of previously reported SLC35A2‐CDG individuals, 27 of
32 (84%; Table S1), were identified by NGS with many of those
affected individuals listed in the online supplemental data of large
sequencing studies (Bosch et al., 2016; Bruneel et al., 2018; Dorre
et al., 2015; Euro, Epilepsy Phenome/Genome, & Epi, 2014; Kimizu
et al., 2017; Kodera et al., 2013; Lelieveld et al., 2016; Ng et al., 2013;
Sim et al., 2018; Westenfield et al., 2018; Winawer et al., 2018; Yates
et al., 2018). This explains why the number of reported subjects cited
varies among studies. A useful online tool that helps to catalog some
publications involving de novo variants is http://denovo‐db.gs.
washington.edu/denovo‐db/.
In our cohort, 29/30 of affected individuals (97%) were
identified by NGS (Table 1). The one exception, CDG‐0389, had
an extremely abnormal CDT result suggestive of a galactosylation
defect, which in combination with her clinical phenotype was
suggestive of SLC35A2‐CDG. Sanger sequencing confirmed the
presence of a de novo c.698T>C (p.Leu233Pro) change (Table 1). In
total, 26/30 (87%) were de novo variants not previously reported,
while a few were recurrent de novo variants p.Arg55Pro,
p.Gln168Ter, p.Ala253Glyfs*100, and p.Val331Ile (Euro, Epilepsy
Phenome/Genome, & Epi, 2014; Ng et al., 2013; Sim et al., 2018;
Westenfield et al., 2018; Winawer et al., 2018; Table 1 and
Figure 1). CDG‐0468 carried the c.502C>T (p.Gln168Ter) and was
part of the Epi4K study mentioned above. The distribution of the
30 variants included 15 missense, seven out‐of‐frame INDELS,
four nonsense, two in‐frame deletions, one loss of an essential
splice site, and one start codon loss (Table 1 and Figure 1).
Only one variant, p.Gly188Ser, was present at very low frequency
(2/133432 alleles) in the gnomAD database (http://gnomad.
broadinstitute.org/; gnomAD r2.0.2 accessed 1.24.2019) of
125,748 exomes and 15,708 whole‐genomes of unrelated indivi-
duals. We previously reported that SLC35A2 does not tolerate
genetic variation, especially in males (Ng et al., 2013). Consistent
with that observation, the gender ratio was 29 females to 1 male
(Table 1). The single male (CDG‐0460) identified in this study did
not appear to be mosaic for the c.944T>C (p.Leu315Pro) based on
his NGS allele reads, which only showed the presence of the
mutant allele in tested blood samples, no other tissues were
studied (data not shown). It should be noted that complete variant
segregation was unavailable for two families. CDG‐0114 carried a
novel c.617del (p.Val206Alafs*143) and because it is generally
accepted that SLC35A2 does not tolerate INDEL variants, it is
unlikely the father, who was unavailable for testing, was a carrier.
CDG‐0248 carried a novel missense variant c.818G>A
(p.Gly273Asp) that was absent from the mother, but the father
was unavailable for testing. However, in a recent separate study
on SLC35A2‐CDG, an unrelated affected individual was identified
carrying the same c.818G>A (p.Gly273Asp) as a de novo variant
showing a slightly abnormal CDT (Vals et al., 2019; doi: 10.1002/
jimd.12055) Two individuals from this paper (CDG‐0389, CDG‐
0469) and the paper from Vals et al. (2019) are shared.
The gnomAD database for the canonical transcript of SLC35A2
(ENST00000247138) contains no hemizygous or heterozygous
variants causing truncation of the protein including no loss of a
start codon, premature stop codons or out‐of‐frame INDELS, or in
frame deletions upstream of the C‐terminal cytoplasmic tail. The
database does contain several in frame deletions within the
cytoplasmic tail that do not disrupt transmembrane domain
(TMD) organization and so are unlikely to disrupt SLC35A2
activity: p.Ala355_Ser356dup (n = 17), p.Ala355_Ser356del (n = 1),
p.Ser356_Gly357del (Sosicka et al., 2014).
In silico modeling to predict the deleterious nature of a specific
variant was performed using the combined annotation dependent
depletion (CADD; http://cadd.gs.washington.edu/) scoring method
version GRCh37‐v1.4 (Kircher et al., 2014). This method was solely
used as a guide to aid in prioritizing variants that would be tested in
our complementation assay. Using the CADD method, all (nonsense
or missense) but one variant scored ≥22, placing it within the top 1%
of predicted deleterious variants (Table 1). Further, 16 (80%) had
CADD scores (>25) in the top 0.5% of predicted deleterious variants
(Table 1).
4 | CLINICAL SUMMARY
In total, we obtained clinical data on 30 affected individuals
(29 females/1 male) from 30 unrelated families. Twenty‐eight
individuals were confirmed by either Sanger sequencing or NGS
analysis of the trio, to harbor de novo variants in SLC35A2 while
the remaining two are strongly suggestive to be de novo as
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mentioned above. In our cohort, 6/30 (20%; Figure 2) pregnancies
experienced some type of fetal anomaly with two possible
skeletal dysplasias and two with pericardial effusions at 20 weeks
that spontaneously resolved by 30 weeks. Individual CDG‐0056
had decreased fetal movements and a breech presentation.
Feeding problems were seen in 22/30 (73%) individuals with
20/30 (67%) having placement of a g‐tube. Consequently, 23/30
(77%) affected individuals displayed clear features of failure to
thrive (Figure 2).
For many CDG types that affect N‐linked glycosylation,
serum transferrin is a useful and reliable tool for the initial
screening of CDG. Abnormal N‐glycans associated with SLC35A2‐
CDG typically display a truncated pattern lacking galactose and
terminal sialic acid (Dorre et al., 2015; Ng et al., 2013). However,
this is not always the case for SLC35A2‐CDG. In fact, of the 32
previously reported subjects, only five (16%) had abnormal CDT
results consistent with SLC35A2‐CDG (Bruneel et al., 2018;
Dorre et al., 2015; Ng et al., 2013; Table S1). Adding further
complexity, at least two of these individuals showed complete
normalization of their CDT by 3 years of age without any specific
therapy (Ng et al., 2013). Since many SLC35A2‐CDG are not
diagnosed until after the age of 3, it begs the question of how
TABLE 1 General information for 30 individuals with SLC35A2‐CDG. Individual ID, gender, genotypes, predicted CADD scores, CDT results
and detection method are provided for the 30 individuals found to carry de novo variants within SLC35A2. Nucleotide numbering for cDNA
uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. SLC35A2
NCBI Accession (NM_001042498.2) and for ENSEMBL (ENST00000376521.6). All cDNA to protein translations were confirmed using
https://mutalyzer.nl/ (WES – Whole Exome Sequencing, WGS – Whole Genome Sequencing) N/A – Not Available
ID Sex cDNA position Protein position Variant status CADD score CDT result Detection method
CDG‐ 0008 F c.523_525del p.Leu175del Novel N/A N/A WES
CDG‐ 0028 F c.193_204del p.Phe65_Thr68del Novel N/A Normal WES
CDG‐ 0045 F c.816G>A p.Trp272Ter Novel 38 Normal Panel
CDG‐ 0052 F c.348del p.Val117Cysfs*27 Novel N/A Normal WES
CDG‐ 0056 F c.562G>A p.Gly188Ser Novel 8.6 N/A WES
CDG‐ 0057 F c.497_501dup p.Gln168Glyfs*183 Novel N/A N/A Panel
CDG‐ 0058 F c.168C>A p.Tyr56Ter Novel 22.2 Normal Panel
CDG‐ 0059 F c.274+2T>C p.? Novel N/A Normal WES
CDG‐ 0114 F c.617del p.Val206Alafs*143 Novel N/A Normal WGS
CDG‐ 0115 F c.856del p.Ala286Leufs*63 Novel N/A N/A WGS
CDG‐ 0116 F c.547C>T p.Gln183Ter Novel 36 Normal Panel
CDG‐ 0149 F c.908T>C p.Leu303Pro Novel 31 Normal WES
CDG‐ 0154 F c.795del p.Phe265Leufs*84 Novel N/A Normal WES
CDG‐ 0164 F c.935C>A p.Ser312Tyr Novel 26.6 Normal WES
CDG‐ 0173 F c.991G>A p.Val331IIe Known 26.4 Normal WES
CDG‐ 0187 F c.211G>A p.Val71Met Novel 26.9 Normal WGS
CDG‐ 0198 F c.346G>C p.Ala116Pro Novel 26.6 N/A Panel
CDG − 0199 F c.302T>C p.Leu101Pro Novel 26.1 Normal WES
CDG‐ 0248 F c.818G>A p.Gly273Asp Novel 23.3 Normal WES
CDG‐ 0265 F c.353C>G p.Pro118Arg Novel 27 Normal Panel
CDG‐ 0266 F c.747_757dup p.Ala253Glyfs*100 Known N/A Normal Panel
CDG‐ 0308 F c.523C>T p.Leu175Phe Novel 26.6 Abnormal Panel
CDG‐ 0332 F c.164G>C p.Arg55Pro Known 26.7 Normal WES
CDG‐ 0389 F c.698T>C p.Leu233Pro Novel 27.8 Abnormal Sanger
CDG‐ 0449 F c.1A>G p.Met1? Novel 23.2 Normal WGS
CDG‐ 0454 F c.569dup p.Gly191Argfs*31 Novel N/A Normal WES
CDG‐ 0460 M c.944T>C p.Leu315Pro Novel 27.4 Abnormal WES
CDG‐ 0468 F c.502C>T p.Gln168Ter Known 36 Normal WES
CDG‐ 0469 F c.389A>G p.Tyr130Cys Novel 28.1 Abnormal WES
CDG‐ 1039 F c.245G>T p.Cys82Phe Novel 28.5 Normal WES
Note. CADD: combined annotation dependent depletion; cDNA: complementary DNA; CDT: carbohydrate deficient transferrin; WES: whole exome
sequencing.
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many of the previously reported subjects may have normalized
their CDT.
In our cohort, 5/21 (24%) individuals who had CDT analysis,
showed abnormal results consistent with SLC35A2‐CDG (Figure 2).
Importantly, among those, three are >3 years of age and one
(CDG‐0469) has shown spontaneous improvement in her CDT
without clinical improvement (Figure S3). While the CDT profile for
CDG‐0469 has markedly improved, the N‐glycans on her serum IgG
have remained normal over the last several years (data not shown).
The remaining two are still under the age of 3, but repeated CDTs
have been consistently abnormal thus far. Among 21 individuals
tested for CDT, 17 used mass spectrometry.
Similar to previously reported subjects, our cohort of SLC35A2‐CDG
individuals had varying degrees of physical and neurodevelopmental
deficiencies, including developmental delay (30/30–100%), epilepsy (25/
30–83%), hypotonia (28/30–93%), microcephaly (13/30–43%), and
abnormal brain imaging results (25/30–83%; Figure 2). White matter
abnormalities 16/30 (53%) and cerebellar atrophy 17/30 (57%)
comprised the majority of the abnormal brain imaging results
(Table S2). Intellectual disability was present in 28/29 (97%) individuals
who could be evaluated (Figure 2). Another major clinical feature
was a recognizable skeletal abnormality, present in 25/30 (83%).
Individuals with skeletal problems usually presented with multiple
features including shortened limbs (9/30–30%), contractures (8/30–
27%), scoliosis (15/30–50%) and hand or finger abnormalities (16/30–
53%; Table S2). These individuals may have shown a greater impairment
of proteoglycan synthesis, which is critical for normal bone development
or perhaps a greater degree of SLC35A2 mosaicism. Facial dysmorphism
was seen in 26/30 (87%) individuals, while ocular abnormalities
comprised 20/30 (67%; Figure 2). Cortical visual impairment (CVI) was
the most frequent ocular abnormality, reported in 13/30 (43%; Table
S2). The main skin finding was inverted nipples 8/30 (27%), although
4/30 (13%) individuals had unusually pigmented areas of skin (Table S2).
Less affected systems included the heart 8/30 (27%) and kidney
1/30 (3%), while liver involvement (mildly elevated transaminases)
was noted in 12/30 (40%) individuals (Figure 2) (Table S2). Four
affected females showed premature signs of puberty. Interestingly,
sensorineural hearing loss, while not often seen in other forms of
CDG was found in three subjects (Table S2).
Finally, SLC35A2‐CDG appears to have a low mortality rate. No
fatalities were seen in the 32 previously reported individuals and in
our group of 30, all but one is still alive. In the most prevalent type of
F IGURE 1 Schematic representation of the SLC35A2 variants present in our 30 individuals. (a) Schematic representation showing exon
location of all 30 SLC35A2 variants identified in this study. (b) Schematic representation showing protein localization of all 30 SLC35A2 variants
identified in this study. SLC35A2 topology was determined using the 3D model generated with PHYRE2 server (Kelley et al., 2015)
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CDG, PMM2‐CDG, 20% of affected individuals die within the first
year of life (de Lonlay et al., 2001; Grunewald, 2009).
4.1 | Optimization of UDP‐Galactose transport
assay
SLC35A2 is known to be a core component of glycosylation,
especially for N‐ and O‐linked, GAG and glycolipid synthesis which
are heavily reliant on galactosylation (Brandli, Hansson, Rodriguez‐
Boulan, & Simons, 1988; Miura et al., 1996; Toma, Pinhal, Dietrich,
Nader, & Hirschberg, 1996). Yet, an unusual biochemical hallmark of
SLC35A2‐CDG is that most affected individuals have either normal
CDT or normal total N‐ and O‐linked glycan compositions (Xia et al.,
2013) Since CDT may not be an effective screening tool for this
particular CDG, many cases with SLC35A2‐CDG are less likely to
be diagnosed. Of the 32 reported SLC35A2‐CDG individuals, only the
original three subjects had a direct measurement of UDP‐galactose
transport assayed using primary fibroblasts (Ng et al., 2013).
Therefore, we set out to develop a robust and reliable biochemical
assay for measuring SLC35A2‐dependent Golgi transport.
Glycosides are small, membrane‐permeable molecules consisting of a
hydrophobic aglycon and a monosaccharide. When localized in the proper
Golgi compartment, glycosides in close proximity to their respective
glycosyltransferase can serve as primers for oligosaccharide biosynthesis
(Sarkar, Fritz, Taylor, & Esko, 1995; Sarkar, Rostand, Jain, Matta, & Esko,
1997). For this reason, glycosides were used to study co‐localization of
glycosyltransferases and nucleotide sugar transporters (Etchison &
Freeze, 1996; Etchison, Srikrishna, & Freeze, 1995;
Kim et al., 2001; Portner, Etchison, Sampath, & Freeze, 1996). We used
glycoside GlcNAcβ−4‐MU as an artificial acceptor to measure SLC35A2‐
dependent UDP‐galactose transport into the Golgi. Specifically, we
hypotonically‐lysed cells and added membrane permeant GlcNAcβ−4‐MU
to load intact Golgi with the glycoside acceptor. When exogenous UDP‐
[6‐3H] galactose is provided, it is transported by SLC35A2 into the Golgi
where it becomes accessible to the colocated β1,4 galactosyltransferase
(β1,4GALT). The colocalization of the donor (transported UDP‐Gal),
acceptor glycoside and transferase within the Golgi allows the
transported UDP‐[6‐3H] galactose to be transferred to GlcNAcβ−4‐MU.
The final reaction product, [6‐3H] Galβ1,4GlcNAcβ−4‐MU, may also
diffuse back across the membranes, but much more slowly (Etchison
et al., 1995). Furthermore, [6‐3H] Galβ1,4GlcNAcβ−4‐MU can be
extended with a terminal sialic acid (Etchison et al., 1995). The great
majority of galactosylated glycoside remains inside the Golgi during the
assay and is extracted with 70% ethanol.
We optimized assay conditions using CHO and CHO‐Lec8 cells.
CHO‐Lec8 is a well‐characterized SLC35A2 mutant, which does not
produce a functional UDP‐galactose transporter and thus is incap-
able of delivering this the donor into the Golgi (Oelmann et al., 2001).
In this study, we used the CHO‐Lec8 line (Stanley, 1981) carrying a
101 bp deletion which results in a premature stop codon.
We optimized GlcNAcβ−4‐MU concentration, reaction tempera-
ture and time (Figure 3a) for permeabilized cells, which were
preincubated with glycoside for 5 min before adding UDP‐[6‐3H]
galactose. Glycoside concentrations were selected (Etchison &
Freeze, 1996; Etchison et al., 1995; Kim et al., 2001; Portner et al.,
1996) based on the formation of [6‐3H] Galβ1,4GlcNAcβ− 4‐MU.
CHO‐Lec8, showed no activity confirming the specificity of the assay
(Figure 3a) and 37°C was the optimal temperature (Figure 3a) with
an incubation time of 45–60min (Figure 3a). To ensure the UDP‐
[6‐3H] galactose incorporation is SLC35A2‐dependent, we performed
F IGURE 2 Clinical summary of 30 individuals with de novo variants in SLC35A2. Clinical information for each of the 30 individuals were
provided by clinicians and summarized as a percentage of affected individuals
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the assay on CHO cells in the presence of 0.025% Triton X‐100, which
is slightly above the critical micelle concentration and will disrupt the
Golgi membrane integrity and therefore dramatically decrease labeling
of GlcNAcβ−4‐MU in the Golgi lumen (Hayes, Freeze, & Varki, 1993).
The detergent abolished all transport (Figure 3b), proving the
approach requires membrane integrity and the colocalization of donor,
acceptor substrates, and glycosyltransferase. Glycoside products were
verified by HPLC as described (Etchison et al., 1995), showing 80%
[6‐3H] Galβ1,4GlcNAcβ−4‐MU and 20% extended by the addition of
2,3 linked sialic acid (data not shown).
Finally, we showed that this approach can be used to determine
the kinetics of UDP‐galactose transport in CHO cells. Under optimal
conditions, we determined the transporter Km as approximately
3.2 µM Vmax of approximately 574 pmol UDP‐galactose/h/mg total
protein in the cell lysate (Figure 3c).
4.2 | UDP‐Galactose transport in fibroblasts
We initially measured UDP‐galactose transport in three commercially
available control fibroblast lines from apparently healthy individuals
(Coriell cell repository GM‐00038, GM‐03348, GM‐05381). Subse-
quently, we assayed ten primary fibroblast lines from individuals with
confirmed de novo variants in SLC35A2, including three previously
characterized SLC35A2‐CDG subjects. Importantly, each SLC35A2‐
CDG‐derived cell line showed varying levels of statistically significant
reductions of UDP‐[6‐3H] galactose transport, while the three controls
showed consistently comparable levels (Figure 4). Two individuals had
nearly no transport activity (CDG‐0389, 0416; Figure 4). CDG‐0416 is
an affected male from another study for whom we only have
biochemical results. However, it is important to note that this individual,
like CDG‐0460, only expressed the mutant allele. Comparing results
from the first three reported individuals, using the transport method by
Ng et al. (2013) to those presented here, yielded comparable results
(Figure 4). We further characterized these fibroblast lines to better
explain these differences in the SLC35A2‐dependent transport activity.
4.3 | SLC35A2 cDNA Allele Ratios
We had previously shown in mosaic males that WT fibroblasts
grew faster than those containing SLC35A2 pathogenic variants.
F IGURE 3 Optimization of the glycoside‐based UDP‐galactose transport assay. (a) GlcNAcβ−4‐MU concentration, temperature and time of
the assay were optimized. Glycoside concentration was tested using CHO (circles) and CHO‐Lec8 (squares) cells. Temperature and time were
optimized only on CHO lines. Transport efficiency at room temperature (diamonds) and 37°C (triangles) was compared using increasing
concentrations of GlcNAcβ−4‐MU. Time curve (asterisk) was assayed at 37°C with 1mM glycoside. (b) UDP‐galactose transport was measured
in CHO cells using optimized conditions. As a negative control CHO‐Lec8 cells were used. Specificity of the assay was determined by treating
CHO cells with 0.025% Trition‐X100 (CHO + TX100). The assay was performed in three biological repetitions. Error bars represent SD.
(c) Michaelis constant and the maximum UDP‐galactose transport velocity were determined for CHO protein in optimized assay conditions.
Each point represents a mean of 3–6 independent biological repetitions using different cell preparations and performed on different days.
Error bars represent SEM. CHO: Chinese hamster ovary; CPM: counts per minute; SEM: standard error of mean
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Since females could have variable proportions of X‐inactivated
cells, it was important to assess the proportions of normal
and variant alleles. To estimate the ratio of WT and mutant
alleles, we took advantage of the fact that each variant creates
either a gain or loss of a particular restriction site (Figure S1 and
Table S3). RNA isolated from control and SLC35A2‐CDG fibro-
blasts was transcribed into cDNA, and PCR amplified and digested
with the appropriate restriction enzyme (Table S3). We found that
CDG‐0416 and CDG‐0460 expressed only the mutant SLC35A2
allele (Figure 5a), which was consistent with the NGS data. In the
other five individuals, we found approximately 4% (CDG‐0389),
20% (CDG‐0187), 51% (CDG‐0468), 87% (CDG‐0469), and 18%
(CDG‐1039) of the WT mRNA remaining (Figure 5a). This
observation, can in part, explain the differences in the UDP‐
galactose transport activity from each subject. Moreover, knowing
the ratio of WT to mutant alleles allowed us to approximate the
contribution of the specific variants on SLC35A2‐dependent
transport activity. However, it should be noted that allele
ratios are likely to vary in different tissues for those individuals
and could also change over time. For example, the variable
allele ratio in the liver can provide a possible explanation for why
many SLC35A2‐CDG individuals have normal CDT results. Over
time, if mutant liver cells are selected against, the majority will be
normal cells.
Based on the measured ratios of WT to mutant alleles, we
attempted to estimate the residual transport activity for each
SLC35A2 protein variant. GM‐00038 transport activity was taken as
a reference for the three controls. We found that the UDP‐galactose
transporter mutant present in CDG‐0187 cells exhibits approximately
30%, CDG‐0389 approximately 7%, CDG‐0416 approximately 15%,
CDG‐0460 approximately 55%, CDG‐0468 approximately 20%, CDG‐
0469 0% and in CDG‐1039 approximately 60% of the WT protein
activity (Figure 5b). However, care must be taken when interpreting
these values. For example, one control line (GM‐05381) exhibited
significantly higher transport activity than the others tested reaching
approximately 125% of GM‐00038 transport efficiency. This indicates
that the transport yield may differ between control lines. For these
reasons, these values are a relative comparison of activity in the
presence of a particular allele ratio.
Furthermore, X‐inactivation can differ between tissues and allele
ratio may change with the increased passage of fibroblast cell lines. In
our cohort, only 4 of 29 female individuals had XCI studies performed
with two being reported as having random XCI, while the other two
F IGURE 4 UDP‐galactose transport
assay in primary fibroblasts. UDP‐[6‐3H]
galactose transport in permeabilized
fibroblast cells with an intact Golgi
apparatus under optimized conditions.
Each assay was performed in three
biological repetitions and expressed
as a percent of the control (*p < 0.05;
**p < 0.005; ***p < 0.001)
F IGURE 5 Determination of the wild‐type to mutant allele ratios in
fibroblasts (a) SLC35A2 complementary DNA allele ratios in primary
fibroblasts from control and SLC35A2‐CDG subjects. Wild‐type to
mutant allele ratios was determined using a restriction enzyme‐based
assay. GM‐00038, GM‐03348, and GM‐05381 cells were used as
controls. Each assay was performed in duplicate to determine the
reproducibility of the assay. (b) UDP‐galactose transporter activity was
calculated based on the allele ratio presented as a percentage of the
GM‐00038 transport activity. To illustrate the activity of the respective
mutant protein, the contribution of wild‐type protein was subtracted
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showed Nonrandom (i.e., skewed) XCI (data not shown). Importantly,
CDG‐0389 had XCI analysis done from three tissue sources; buccal cells,
fibroblasts, and whole blood using a previously reported method (Allen,
Zoghbi, Moseley, Rosenblatt, & Belmont, 1992). Nonrandom inactivation
was seen in both buccal (94:6) and cultured fibroblasts (85:15), while
blood samples (57:42) appeared to be random. Ratios greater than 80:20
are considered to be indicative of Nonrandom X inactivation.
4.4 | Western blot analysis
Primary fibroblasts were used for western blot analysis of SLC35A2
protein from seven affected individuals to determine whether the
decrease in UDP‐galactose transport could be attributed to a decrease
in SLC35A2 protein. We found that CDG‐0389, who carriers c.698T>C
(p.Leu233Pro), had no detectable SLC35A2 protein, while a slight
decrease was observed in CDG‐0468, who harbors a premature stop
codon c.502C>T (p.Gln168Ter; Figure 6a andTable 1). In the other five
subjects, SLC35A2 protein levels were not affected by the de novo
variant (Figure 6a). Statistical significance was calculated on multiple
blots to run on separate biological replicates (Figure 6b)
4.5 | Immunofluorescence staining of fibroblasts
Fibroblasts from both controls and subjects were seeded onto
coverslips, grown for 48 hr and stained using anti‐SLC35A2 antibody
and VVL lectin. This lectin specifically recognizes terminal GalNAc
present in O‐glycans, which is usually masked by the addition of
galactose eliminating lectin binding. Since VVL is an established
marker, which exhibits significantly higher amount in cells with UDP‐
galactose transporter defects (Maszczak‐Seneczko, Olczak, Wunder-
lich, & Olczak, 2011, Ng et al., 2013), we expected to see elevated
VVL reactivity in fibroblasts from the subjects. Confocal microscopy
confirmed that SLC35A2 protein properly localized to the Golgi
apparatus in all CDG cells (Figure 7), but the predicted increase in
VVL binding was observed in only two of seven SLC35A2‐CDG
fibroblasts (CDG‐0468 and CDG‐0469). The other cells exhibit a
similar staining pattern and fluorescence intensity as the control
lines. There are several possible explanations for this effect. First, the
overall biosynthesis of O‐glycans might be significantly depleted in
these cells leading to reduction in terminal GalNAc. Second, other
monosaccharides can be attached to GalNAc, blocking VVL binding.
Finally, O‐glycans might not be a representative marker of a
galactosylation defect in all individuals, while N‐glycans, proteogly-
cans or glycolipids could be better in some than others.
Western blot results revealed that both CDG‐0389 and
CDG‐0468 produced significantly reduced levels of the SLC35A2
protein (Figure 6a), which was consistent with the immunofluores-
cence results (Figure 7).
4.6 | CHO Lec8 complementation assays
We set out to determine if the CHO mutant cell line Lec8, which lacks
all galactosylation, could be used for a cell‐based complementation
assay. We expected that only WT or benign SLC35A2 variants would
restore UDP‐galactose transport and galactosylation in the mutant
while expressing a pathogenic variant would dramatically lower
transport and galactosylation. We generated five stable Lec8 lines
expressing WT or specific SLC35A2 variants for which we also had
primary fibroblasts for comparison. Expression of these variants was
driven off either weak or strong promoters. The first method was the
UDP‐galactose transport assay and the second was the immunofluor-
escence staining with VVL lectin. In the transport assay, WT SLC35A2
was able to correct the transport defect in Lec8. However, the
p.Cys82Phe, p.Leu233Pro, p.Leu315Pro, and the protein change present
in CDG‐0416 were also able to complement the Lec8 defect (Figure 8a).
In contrast, these results were not seen in fibroblasts from individuals
with the same SLC35A2 variants (Figure 4).
Next, we tested if stably transfected cells had reduced VVL
lectin reactivity due to the masking of the VVL epitope by
galactose. While the tested variants localized properly to the Golgi
apparatus (Figure 8b), all were equal to WT in correcting the
galactosylation defect (Figure 8b). This cannot be true since these
mutants are not capable of transporting UDP‐galactose as seen
using the primary fibroblast. Only overexpression of a loss of
function variant, p.Val131del, did not correct CHO‐Lec8 pheno-
type (Figure 8). The data suggest that simply over‐expressing
SLC35A2 variants in Lec8 or any cell line could have unforeseen
consequences and not be truly reflective of physiological condi-
tions seen in fibroblast from affected individuals cells.
F IGURE 6 Western blot analysis of SLC35A2 protein from
primary fibroblast. (a) Western blot analysis of SLC35A2 protein
from a total of seven SLC35A2‐CDG fibroblast lines as well as three
controls (GM‐00038, GM‐03348, and GM‐05381). Anti‐α‐tubulin
antibody was used as a loading control. (b) Quantification was
performed by normalizing SLC35A2 to α‐tubulin from four
independent blots using two biological replicates collected on
separate days with error bars calculated as a standard deviation
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4.7 | Biochemical summary
We characterized seven affected individuals and demonstrate that
currently, only subject‐derived fibroblasts provide a valid method
to measure UDP‐galactose transport to confirm pathogenicity of
the variants (Figure 4 and Table 2). Only two of seven lines (CDG‐
0389 and CDG‐0468) produced a significantly decreased amount
of SLC35A2 protein (Figures 6 and 7; Table 2). In contrast, the
other hallmark expected to be present in all SLC35A2‐CDG cells is
increased binding of VVL to terminal GalNAc; however, this feature
was found only in 2 out of 7 fibroblasts (CDG‐0468 and CDG‐0469;
Figure 7 and Table 2). It is noteworthy that the percentage of VVL
positive cells assigned by immunofluorescence staining corre-
sponds with the determined cDNA mutant to WT allele ratios
(Figure S4 and Table 2). Because of the limited access to fibroblasts
from affected individuals, we tried to establish an alternative
method, using complemented CHO‐Lec8 cells. Attempts to make
stable CHO‐Lec8 cells expressing SLC35A2 driven off a CMV
promoter often resulted in cell death. Using a weaker EF‐1
promoter resulted in successful stable SLC35A2 expression;
however, we clearly show that overexpression of subject‐specific
variants resulted in a phenotype similar to that of the WT protein
(Figure 8 and Table 2). Thus, CHO‐Lec8 complemented cells are not
a suitable diagnostic tool.
5 | DISCUSSION
Here we describe the identification and characterization of 30
individuals with SLC35A2‐CDG, which to date is the single largest
study for this rare disorder. As in previously reported SLC35A2‐CDG
subjects, all 30 individuals in our cohort had profound neurological
and developmental impairments. Many (83%), but not all had
F IGURE 7 Immunofluorescence staining of primary fibroblasts. To assess glycosylation between control (GM‐00038, GM‐03348, and GM‐
05381) and subject fibroblasts (CDG‐0187, CDG‐0389, CDG‐0416, CDG‐0460, CDG‐0468, CDG‐0469 and CDG‐1039) VVL lectin was used
(green). This lectin specifically recognizes terminal GalNAc present in O‐glycans, which is usually masked by galactose and blocks the lectin
reactivity. UDP‐galactose transporter was counterstained with anti‐SLC35A2 antibody (red). Scale bar 20 µm
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epilepsy. We find a large percentage (83%) of individuals also
displayed some form of skeletal abnormality, which has not been
previously highlighted.
Since many affected individuals with SLC35A2‐CDG do not
show an abnormal CDT or abnormal total serum N‐ or O‐glycan
profile, we set out to establish a reliable and robust method for
assaying SLC35A2‐dependent transport activity in primary fibro-
blasts to characterize potential VUS. While sometimes difficult to
obtain, primary fibroblasts allow the direct measurement of
SLC35A2‐dependent transport activity and WT to mutant allele
ratios. The latter point could help explain why some individuals
still retain significant transport activity in fibroblasts.
It would be ideal to develop additional nonfibroblast lines for
verifying subject‐relevant variants or reclassifying VUS. Early work
establishing the role for SLC35A2 in galactosylation had been primarily
performed using nonhuman mutant cell lines from murine mammary
carcinoma cells (FM3A), Chinese hamster ovary (CHO) cells, and Madin‐
Darby Canine Kidney (MDCK) cells (Ishida et al., 1999; Oelmann et al.,
2001; Olczak & Guillen, 2006; Stanley, 1981). We attempted to stably
express subject‐specific SLC35A2 variants in CHO‐Lec8 cells but could
not achieve consistent results in comparison to fibroblasts from
SLC35A2‐CDG individuals, despite using expression vectors containing
either weak or strong promoters.
Currently, only subject‐derived fibroblasts provide a valid method to
measure UDP‐galactose transport to confirm pathogenicity of the
variants. We show by immunofluorescence staining that resident glycans
may not always lead to a clear conclusion and may partially explain why a
large group of affected individuals does not exhibit any changes in
transferrin glycosylation. We have established here that CHO‐Lec8 cells,
which do not produce their own functional UDP‐galactose transporter,
cannot be used for the purpose of complementation. All tested fibroblasts
exhibited impaired UDP‐galactose transport; however, when selected
variants were overexpressed in CHO‐Lec8 cells, the respective proteins
appeared fully functional (Figure 8). We believe that using complemented
cell lines to assay SLC35A2 activity is not a suitable approach. In the end,
if fibroblast analysis is not possible, generating individualized CRISPR/
Cas9 edited cell lines might be needed for accurate characterization of
specific variants.
F IGURE 8 Characterization of CHO‐Lec8 stable clones expressing SLC35A2. (a) UDP‐[6‐3H] galactose transport assay in parental CHO,
CHO‐Lec8, and CHO‐Lec8 cells overexpressing respective variants of SLC35A2 protein. For better comparison, fibroblast results from control
(GM‐00038) and four affected individuals (CDG‐0389, CDG‐0416, CDG‐0460, CDG‐1039) were plotted. The transport for SLC35A2‐CDG
fibroblasts was expressed as the predicted activity of mutant transporter by subtracting the contribution of wild type protein, based on the
calculated allele ratio. Each assay was performed in two biological repetitions. (b) Immunofluorescence staining of CHO‐Lec8 cells
overexpressing UDP‐galactose transporter. Overexpressed HA‐tagged SLC35A2 protein was detected with anti‐HA antibody (green).
VVL lectin staining was used to detect glycosylation changes between CHO‐Lec8 cells which do or do not overexpress the transporter (red).
Stable transfectants, but not clonal populations were analyzed. Scale bar 20 µm. CHO: Chinese hamster ovary; VVL: Vicia villosa lectin
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To date only 5/32 previously reported individuals had abnormal
transferrin glycosylation (Bruneel et al., 2018; Dorre et al., 2015; Ng
et al., 2013). Similarly, in our cohort 5/21 subjects had abnormal results
that were consistent with SLC35A2‐CDG. Analysis of SLC35A2‐CDG
fibroblasts also revealed that only two out of seven had impaired
galactosylation (Figure 7). It remains unclear why these lines do not
show galactosylation deficiencies when UDP‐galactose transport mea-
sured in fibroblasts is clearly deficient. However, such a result is not
unprecedented. CRISPR mediated SLC35A5 knock‐out in HepG2 cells
causes a significant decrease in UDP‐GlcNAc, UDP‐GalNAc, and UDP‐
GlcA Golgi transport without affecting global glycosylation (Sosicka et al.,
2019). Residual transport activity was seen in fibroblasts (Figure 4 and
Figure 5b) may be sufficient for normal glycosylation. Alternatively,
another sugar nucleotide transporter might contribute to or compensate
for decreased SLC35A2‐dependent UDP‐galactose transport. A possible
candidate is the UDP‐GlcNAc transporter, which can partially restore
galactosylation when overexpressed in CHO‐Lec8 and MDCK‐RCAr cells
(Maszczak‐Seneczko, Olczak, Jakimowicz, & Olczak, 2011).
With a large number of mutations available, we wanted to describe
the variants based on protein structural features. The previously reported
missense variants, Arg55, Phe65, Ala170, Leu172, Val206, Ser213,
Val331, and, of those reported here, Arg55, Val71, Cys82, Leu101,
Ala116, Leu175, Gly188, Gly273, Leu315, Val331 appear to be localized
within one of the ten hydrophobic transmembrane domains (TMD)
predicted by UNIPROT, suggesting that mutations disrupt TMD
organization. Pathogenic variants have not yet been identified with the
cytoplasmic tail of SLC35A2, and previous reports suggest this region
might be dispensable for its function (Sosicka et al., 2014).
Different topology prediction programs do not all agree. For
example, four independent in silico tools suggest eight TMD and
cytoplasmic loop 2 linking TMD2 and TMD3 is approximately 81
amino acid (88–169), while in UNIPROT predicts ten TMD and
cytoplasmic loop 2 with 8 amino acid. (Figure S5). Although the
crystal structure for SLC35A2 has not been solved, the GDP‐
mannose transporter from Saccharomyces cerevisiae (vrg4) has, and
clearly shows ten TMD (Parker & Newstead, 2017). Using this
template, we modeled SLC35A2 3D using the PHYRE2 server (Kelley,
Mezulis, Yates, Wass, & Sternberg, 2015) producing ten TMD, with a
slightly different distribution than that assigned by UNIPROT or
other in silico prediction tools (Figure S5). Still, the majority of
variants were localized to TMD (Figure 1).
By combining the data from the UDP‐galactose transport assay
and cDNA allele ratio analysis allows an estimate of the activity of
each SLC35A2 mutant. Based on these data, UDP‐galactose
transporter activity is reduced by approximately 70% in CDG‐0187
when compared to the WT protein, while CDG‐0389 (~95%), CDG‐
0416 (~85%), CDG‐0460 (~45%), CDG‐0468 (~75%) and CDG‐1039
(~40%) are also significantly reduced (Figure 5b). However, this
assumption does not consider the total amount of SLC35A2 protein
based on western blot analysis. For example, the level of UDP‐
galactose transporter protein in CDG‐0389 fibroblasts is dramati-
cally reduced compared to both control cells as well as other
SLC35A2‐CDG fibroblast lines.T
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The clinical and biochemical severity of females could vary due to
XCI in different cell types. For instance, in CDG‐0389, XCI from
buccal and fibroblast were heavily skewed indicating “Nonrandom”
inactivation while blood samples were not. Importantly, XCI results
from cultured fibroblast support those seen using our allele ratio
assay and western blot assay results.
While there are no available therapies for SLC35A2‐CDG, a
single case report shows an improved CDT profile in response to oral
D‐galactose (Dorre et al., 2015). However, it is unclear whether this
response was due to D‐galactose, because we know that SLC35A2‐
CDG CDT profiles change over time, (Ng et al., 2013). Controlled,
long‐term studies with clinically relevant measurements will be
required to assess any benefits of oral D‐galactose as a therapy for
these individuals.
In conclusion, we present clinical, molecular and functional
biochemical data on 30 individuals with SLC35A2‐CDG to further
expand the spectrum of this rare disorder and increases the number of
known subjects to 62. We validated the UDP‐galactose transporter
assay in all five available subject fibroblasts. Cells from the other
25 subjects were unavailable and must, therefore, be considered as
likely pathogenic variants.
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